
zzso chronic zzso leukemia zzso is characterized by zzso expanded and zzso zzso populations of B zzso with impaired zzso zzso This occurs as a result of multiple genetic and zzso zzso including zzso aberrations and zzso region zzso often zzso on zzso signaling pathways that are essential to normal zzso zzso zzso and zzso The zzso zzso zzso zzso signaling is one such zzso zzso by zzso B cells, as exemplified by the early phase clinical success achieved by zzso agents targeting key players involved in the zzso Such new targeted agents, including those that inhibit the function of zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso and zzso zzso 2 zzso along with the current standard therapy zzso zzso with or without zzso depleting zzso agent zzso zzso zzso zzso should expand the zzso for zzso zzso We review the therapeutic agents currently in clinical development which target different zzso of the zzso zzso zzso and discuss their overlapping and discriminating zzso opportunities in the context of zzso zzso 

